Nancy U. Lin, MD
Associate Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers Director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nancy U. Lin, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:35 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05721248 · STOP-HER2: Stopping Trastuzumab in HER2+ MBCDana-Farber Cancer Institute · active not recruiting · Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
- Ph3NCT04739761 · A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerAstraZeneca · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT03483012 · Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain MetastasisDana-Farber Cancer Institute · completed · Breast Cancer
- Ph2NCT01560416 · Fulvestrant With or Without Ganetespib in HR+ Breast CancerDana-Farber Cancer Institute · completed · Breast Cancer
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Can a subset of patients with HER2+ metastatic breast cancer be cured?K08CA252639 · NCI · DANA-FARBER CANCER INST · PI Heather Anne Parsons · fiscal years 2021 to 2025Named on NCT05721248
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.